retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism Retatrutide: How GLP-1/GIP/Glucagon Receptor Agonism Differs From Existing Compounds Frontiers | Glucagon-like peptide-1 and

Brierley DI, de Lartigue G

This shift reflects a deeper transformation

One in eight Americans are taking or have taken a glucagon-like peptide-1 receptor agonist (GLP-1)

The SELECT trial, which evaluated semaglutide 2.4 mg against placebo for cardiovascular outcomes in patients with overweight and obesity without type 2 diabetes, showed significant decreases in total cholesterol, LDL-C, and triglycerides and an increase in HDL-C at 39.8 months [48]

For researchers managing their own protocols, understanding the mechanism behind the heart rate effect removes the anxiety of the unknown and replaces it with informed, measured decision-making